{"id":53792,"date":"2026-01-12T21:52:30","date_gmt":"2026-01-12T13:52:30","guid":{"rendered":"https:\/\/flcube.com\/?p=53792"},"modified":"2026-01-12T21:52:32","modified_gmt":"2026-01-12T13:52:32","slug":"biocytogen-licenses-adc-programs-to-acepodia-in-option-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53792","title":{"rendered":"Biocytogen Licenses ADC Programs to Acepodia in Option Deal"},"content":{"rendered":"\n<p><strong>Biocytogen Pharmaceuticals (Beijing) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688796:SHA\">SHA: 688796<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2315:HKG\">HKG: 2315<\/a>) announced an <strong>option and license agreement<\/strong> with <strong>Acepodia<\/strong>, a Taiwan\/California\u2011based immune cell engager specialist, granting Acepodia options to obtain <strong>global exclusive licenses<\/strong> for two of Biocytogen\u2019s <strong>bispecific antibody\u2011drug conjugate (BsADC) programs<\/strong>. The partnership builds on a <strong>January\u202f2024 collaboration<\/strong> that combined Biocytogen\u2019s <strong>RenLite fully human common light chain antibody discovery platform<\/strong> with Acepodia\u2019s <strong>Antibody\u2011Dual Drug Conjugate (AD2C) technology<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (688796.SH\/02315.HK)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Acepodia Inc. (6976:TT)<\/td><\/tr><tr><td><strong>Assets<\/strong><\/td><td>Two bispecific ADC (BsADC) programs<\/td><\/tr><tr><td><strong>Agreement Structure<\/strong><\/td><td>Option and license deal<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Biocytogen RenLite platform + Acepodia AD2C technology<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront option fee (undisclosed), option exercise fees, development\/regulatory\/commercial milestones, sales royalties<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global exclusive licenses (if options exercised)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platforms\">Technology Platforms<\/h2>\n\n\n\n<p><strong>Biocytogen RenLite Platform<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fully human common light chain antibody discovery platform<\/strong><\/li>\n\n\n\n<li>Generates <strong>bispecific antibodies with reduced immunogenicity<\/strong><\/li>\n\n\n\n<li>Enables <strong>streamlined manufacturing and improved developability<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Acepodia AD2C Technology<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antibody\u2011Dual Drug Conjugate<\/strong> platform for <strong>dual\u2011payload ADCs<\/strong><\/li>\n\n\n\n<li>Enhances <strong>tumor\u2011specific cytotoxicity<\/strong> and <strong>overcomes resistance mechanisms<\/strong><\/li>\n\n\n\n<li><strong>Synergistic combination<\/strong> with RenLite enables <strong>novel BsADC architectures<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>For Biocytogen<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Monetization<\/strong>: Leverages RenLite platform for <strong>global BsADC partnerships<\/strong> beyond internal pipeline<\/li>\n\n\n\n<li><strong>Non\u2011Dilutive Funding<\/strong>: Option fees and milestones provide <strong>capital for R&amp;D expansion<\/strong><\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Acepodia partnership <strong>validates BsADC strategy<\/strong>, attracting additional global licensees<\/li>\n<\/ul>\n\n\n\n<p><strong>For Acepodia<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Acceleration<\/strong>: Gains <strong>access to novel BsADC candidates<\/strong> for <strong>solid tumor and hematologic malignancy<\/strong> programs<\/li>\n\n\n\n<li><strong>Manufacturing Advantage<\/strong>: RenLite platform reduces <strong>CMC complexity<\/strong> associated with bispecific antibodies<\/li>\n\n\n\n<li><strong>Global Reach<\/strong>: <strong>Exclusive licenses<\/strong> enable <strong>worldwide development and commercialization<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-bispecific-adcs\">Market Opportunity: Bispecific ADCs<\/h2>\n\n\n\n<p><strong>Global ADC Market<\/strong>: <strong>$6.5\u202fbillion<\/strong> (2025), projected <strong>$15\u202fbillion<\/strong> by 2030, growing at <strong>18% CAGR<\/strong><\/p>\n\n\n\n<p><strong>Bispecific ADC Sub\u2011Segment<\/strong>: Emerging class with <strong>$2\u20113\u202fbillion<\/strong> potential by 2030, targeting <strong>resistant tumor populations<\/strong><\/p>\n\n\n\n<p><strong>Key Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Targeting<\/strong>: Overcomes <strong>antigen heterogeneity<\/strong> and <strong>resistance<\/strong><\/li>\n\n\n\n<li><strong>Enhanced Payload Delivery<\/strong>: <strong>Dual warheads<\/strong> increase <strong>tumor cell kill rate<\/strong><\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: <strong>First BsADC platform<\/strong> with <strong>global licensing traction<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Platform<\/th><th>ADC Type<\/th><th>Stage<\/th><th>Key Differentiator<\/th><\/tr><\/thead><tbody><tr><td><strong>Biocytogen + Acepodia<\/strong><\/td><td>RenLite + AD2C<\/td><td>Bispecific ADC<\/td><td><strong>Discovery \u2192 IND<\/strong><\/td><td><strong>Dual payload, reduced immunogenicity<\/strong><\/td><\/tr><tr><td><strong>Daiichi\u2011Sankyo<\/strong><\/td><td>DXd platform<\/td><td>Monospecific ADC<\/td><td>Marketed (Enhertu)<\/td><td>Proven payload\u2011linker technology<\/td><\/tr><tr><td><strong>Seagen (Pfizer)<\/strong><\/td><td>ADC technology<\/td><td>Monospecific ADC<\/td><td>Marketed (Adcetris)<\/td><td>Established track record<\/td><\/tr><tr><td><strong>Mersana<\/strong><\/td><td>Dolaflexin<\/td><td>ADC<\/td><td>Phase\u202fII<\/td><td>Flexible payload loading<\/td><\/tr><tr><td><strong>Zymeworks<\/strong><\/td><td>Azymetric<\/td><td>Bispecific ADC<\/td><td>Phase\u202fI<\/td><td>Biparatopic binding<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Moat<\/strong>: RenLite\u2019s <strong>common light chain<\/strong> and AD2C\u2019s <strong>dual\u2011payload design<\/strong> create <strong>first\u2011in\u2011class BsADCs<\/strong> with <strong>10\u2011year IP protection<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p><strong>Platform Value<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront Option Fee<\/strong>: Estimated <strong>USD\u202f3\u20118\u202fmillion<\/strong> per program (based on comparable deals)<\/li>\n\n\n\n<li><strong>Milestone Potential<\/strong>: <strong>USD\u202f50\u2011100\u202fmillion<\/strong> per asset (IND, Phase\u202fI, II, BLA)<\/li>\n\n\n\n<li><strong>Royalties<\/strong>: <strong>Mid\u2011single digit to low\u2011double digit<\/strong> on net sales<\/li>\n<\/ul>\n\n\n\n<p><strong>Pipeline Leverage<\/strong>: Success could trigger <strong>5\u201110 additional RenLite\u2011based partnerships<\/strong>, creating <strong>USD\u202f500\u202fmillion\u20111\u202fbillion<\/strong> in cumulative deal value.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Biocytogen\u2011Acepodia partnership\u2019s financial terms, clinical development timelines, and market potential. Actual results may differ materially due to clinical validation risks, competitive dynamics, and regulatory acceptance of novel BsADCs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3101,35,1519,1214,4547],"class_list":["post-53792","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-acepodia","tag-adc-xdc","tag-biocytogen-pharmaceuticals","tag-hkg-2315","tag-sha-688796"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biocytogen Licenses ADC Programs to Acepodia in Option Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement with Acepodia, a Taiwan\/California\u2011based immune cell engager specialist, granting Acepodia options to obtain global exclusive licenses for two of Biocytogen\u2019s bispecific antibody\u2011drug conjugate (BsADC) programs. The partnership builds on a January\u202f2024 collaboration that combined Biocytogen\u2019s RenLite fully human common light chain antibody discovery platform with Acepodia\u2019s Antibody\u2011Dual Drug Conjugate (AD2C) technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53792\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Licenses ADC Programs to Acepodia in Option Deal\" \/>\n<meta property=\"og:description\" content=\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement with Acepodia, a Taiwan\/California\u2011based immune cell engager specialist, granting Acepodia options to obtain global exclusive licenses for two of Biocytogen\u2019s bispecific antibody\u2011drug conjugate (BsADC) programs. The partnership builds on a January\u202f2024 collaboration that combined Biocytogen\u2019s RenLite fully human common light chain antibody discovery platform with Acepodia\u2019s Antibody\u2011Dual Drug Conjugate (AD2C) technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53792\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T13:52:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T13:52:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53792#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53792\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen Licenses ADC Programs to Acepodia in Option Deal\",\"datePublished\":\"2026-01-12T13:52:30+00:00\",\"dateModified\":\"2026-01-12T13:52:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53792\"},\"wordCount\":510,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Acepodia\",\"ADC \\\/ XDC\",\"Biocytogen Pharmaceuticals\",\"HKG: 2315\",\"SHA: 688796\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53792#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53792\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53792\",\"name\":\"Biocytogen Licenses ADC Programs to Acepodia in Option Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T13:52:30+00:00\",\"dateModified\":\"2026-01-12T13:52:32+00:00\",\"description\":\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement with Acepodia, a Taiwan\\\/California\u2011based immune cell engager specialist, granting Acepodia options to obtain global exclusive licenses for two of Biocytogen\u2019s bispecific antibody\u2011drug conjugate (BsADC) programs. The partnership builds on a January\u202f2024 collaboration that combined Biocytogen\u2019s RenLite fully human common light chain antibody discovery platform with Acepodia\u2019s Antibody\u2011Dual Drug Conjugate (AD2C) technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53792#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53792\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53792#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Licenses ADC Programs to Acepodia in Option Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen Licenses ADC Programs to Acepodia in Option Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement with Acepodia, a Taiwan\/California\u2011based immune cell engager specialist, granting Acepodia options to obtain global exclusive licenses for two of Biocytogen\u2019s bispecific antibody\u2011drug conjugate (BsADC) programs. The partnership builds on a January\u202f2024 collaboration that combined Biocytogen\u2019s RenLite fully human common light chain antibody discovery platform with Acepodia\u2019s Antibody\u2011Dual Drug Conjugate (AD2C) technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53792","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Licenses ADC Programs to Acepodia in Option Deal","og_description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement with Acepodia, a Taiwan\/California\u2011based immune cell engager specialist, granting Acepodia options to obtain global exclusive licenses for two of Biocytogen\u2019s bispecific antibody\u2011drug conjugate (BsADC) programs. The partnership builds on a January\u202f2024 collaboration that combined Biocytogen\u2019s RenLite fully human common light chain antibody discovery platform with Acepodia\u2019s Antibody\u2011Dual Drug Conjugate (AD2C) technology.","og_url":"https:\/\/flcube.com\/?p=53792","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T13:52:30+00:00","article_modified_time":"2026-01-12T13:52:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53792#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53792"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen Licenses ADC Programs to Acepodia in Option Deal","datePublished":"2026-01-12T13:52:30+00:00","dateModified":"2026-01-12T13:52:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53792"},"wordCount":510,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Acepodia","ADC \/ XDC","Biocytogen Pharmaceuticals","HKG: 2315","SHA: 688796"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53792#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53792","url":"https:\/\/flcube.com\/?p=53792","name":"Biocytogen Licenses ADC Programs to Acepodia in Option Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T13:52:30+00:00","dateModified":"2026-01-12T13:52:32+00:00","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement with Acepodia, a Taiwan\/California\u2011based immune cell engager specialist, granting Acepodia options to obtain global exclusive licenses for two of Biocytogen\u2019s bispecific antibody\u2011drug conjugate (BsADC) programs. The partnership builds on a January\u202f2024 collaboration that combined Biocytogen\u2019s RenLite fully human common light chain antibody discovery platform with Acepodia\u2019s Antibody\u2011Dual Drug Conjugate (AD2C) technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53792#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53792"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53792#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Licenses ADC Programs to Acepodia in Option Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53792"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53792\/revisions"}],"predecessor-version":[{"id":53793,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53792\/revisions\/53793"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}